Overcoming challenges of treating inflammatory bowel disease in pregnancy

References

• Mountifield R, Bampton P, Prosser R, et al. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15:720–725.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scand J Gastroenterol. 1983;18(6):735–742.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Andreasson B, Bondesen S, et al. Pregnancy in Crohn’s disease. Scand J Gastroenterol. 1984;19(6):724–732.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Sandborn W, Li D, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106–1112.
   PubMed Web of Science ®Google Scholar
• Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut. 1980;21:469–474.
   PubMed Web of Science ®Google Scholar
• Khosla R, Willoughby CP, Jewell DP. Crohn’s disease and pregnancy. Gut. 1984;25:52–56.
   PubMed Web of Science ®Google Scholar
• Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med. 1986;79(4):221–225.
   PubMed Web of Science ®Google Scholar
• Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom study of 209 pregnant women. Aliment Pharmacol Ther. 2013;38:501–512.
   PubMed Web of Science ®Google Scholar
• Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):460–466.
   PubMed Web of Science ®Google Scholar
• Ujihara M, Ando T, Ishiguro K, et al. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. BMC Res Notes. 2013;6:210.
   PubMedGoogle Scholar
• Tavernier N, Fumery M, Peyrin-Biroulet L, et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:847–853.
   PubMed Web of Science ®Google Scholar
• Ban L, Tata L, Fiaschi L, et al. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 2014;146:76–84.
   PubMed Web of Science ®Google Scholar
• Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther. 2011;34:724–734.
   PubMed Web of Science ®Google Scholar
• Getahun D, Fassett M, Longstreth G, et al. Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol. 2014;34:435–440.
   PubMed Web of Science ®Google Scholar
• Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis. 2011;17:795–801.
   PubMed Web of Science ®Google Scholar
• Bröms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20:1091–1098.
   PubMed Web of Science ®Google Scholar
• Stephansson O, Larsson H, Pedersen L, et al. Crohn’s disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol. 2010;8(6):509–515.
   PubMed Web of Science ®Google Scholar
• Molnár T, Farkas K, Nagy F, et al. Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. Scand J Gastroenterol. 2010;45:1302–1306.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, Van Der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318–321.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling [Federal Register Web Site]. [2014; cited 2016 Nov 1]. Available from: http://federalregister.gov\a\2014.28241.
   Google Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.
   PubMedGoogle Scholar
• Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol. 2003;67(12):968–970.
   PubMed Web of Science ®Google Scholar
• Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203–1209.
   PubMed Web of Science ®Google Scholar
• Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240–261.
   PubMedGoogle Scholar
• Nørgård B, Pedersen L, Fonager K, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther. 2003;17:827–834.
   PubMed Web of Science ®Google Scholar
• Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut. 2011;60:198–203.
   PubMed Web of Science ®Google Scholar
• Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79:696–701.
   PubMed Web of Science ®Google Scholar
• Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol. 2009;85:647–654.
   PubMed Web of Science ®Google Scholar
• Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:15–22.
   PubMed Web of Science ®Google Scholar
• Jharap B, de Boer NKH, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut. 2014;63:451–457.
   PubMed Web of Science ®Google Scholar
• Wiles K, Chandiramani M, Jiwani S, et al. A retrospective study of anaemia in neonates exposed to thiopurines in utero. Gut. 2015 Dec 29. doi:10.1136/gutjnl-2015-310984. [ Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433–440.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Martin C, Sandler RS, et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142:S149.
   Web of Science ®Google Scholar
• de Meij TGJ, Jharap B, Kneepkens CMF, et al. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:38–43.
   PubMed Web of Science ®Google Scholar
• Amin J, Huang B, Yoon J, et al. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis. 2015;21:445–452.
   PubMed Web of Science ®Google Scholar
• Goel RM, Blaker P, Mentzer A, et al. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis. 2015;6(3):138–146.
   PubMed Web of Science ®Google Scholar
• Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385–2392.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846–1854.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan B, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107:1409–1422.
   PubMed Web of Science ®Google Scholar
• Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363–373.
   PubMed Web of Science ®Google Scholar
• Jürgens M, Brand S, Filik L, et al. Safety of adalimumab in Crohn’s disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis. 2010;16:1634–1636.
   PubMed Web of Science ®Google Scholar
• McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during and after pregnancy. Inflamm Bowel Dis. 2016;22(1):213–231.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Vermeire S, Wolf DC, et al. Tu1320 Pregnancy outcomes after exposure to certolizumab pegol: updated results from safety surveillance. Gastroenterology. 2015;148(4suppl 1):S858–S859.
   Google Scholar
• Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426–1438.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Loftus EV J, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174.
   PubMed Web of Science ®Google Scholar
• Bröms G, Granath F, Ekbom A, et al. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol. 2016;14:234–241.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:283–311.
   PubMed Web of Science ®Google Scholar
• van der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010;4:493–510.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214–223.
   PubMed Web of Science ®Google Scholar
• Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228–233.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–292.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734–757.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, Christensen A, Gibson PR, et al. Adalimumab and infliximab levels in neonates (ERA Study). Gastroenterology. 2015;148(4 suppl):S108.
   Google Scholar
• Deepak P, Stobaugh DJ. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:1035–1043.
   PubMed Web of Science ®Google Scholar
• Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis. 2014;20(3):495–501.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17:958–961.
   PubMed Web of Science ®Google Scholar
• Cristiano L, Friend S, Bozic C, et al. Evaluation of pregnancy outcomes from Tysabri (natalizumab) pregnancy exposure registry [abstract]. Neurology. 2013;80:P02.217.
   Web of Science ®Google Scholar
• Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. Prospective, Controlled Observational Study. Mult Scler. 2015;21:198–205.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Dubinsky M, Vermeire S, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. J Crohns’ Colitis. 2015;9(suppl 1):S361–S362.
   Google Scholar
• Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136–151.
   PubMed Web of Science ®Google Scholar
• de Lima A, Zelinkova Z, van der Woude CJ. A prospective study of the safety of lower gastrointestinal endoscopy during pregnancy in patients with inflammatory bowel disease. J Crohns’ Colitis. 2015;9:519–524.
   PubMed Web of Science ®Google Scholar